Pulmonary Edema Therapeutics Market is Segmented By Drug Class (Diuretics, Opioid Analgesics, Vasodilators, Antihypertensives, Inotropes, Others), By Type (Cardiogenic Pulmonary Edema, Non-cardiogenic Pulmonary Edema), By Route of Administration (Oral, Intravenous), By Distribution Channel (Hospital, Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Pulmonary Edema Therapeutics Market Overview
Pulmonary Edema Therapeutics Market is estimated to reach at a high CAGR 3.3% during the forecast period (2024-2031).
Pulmonary edema is a disorder that occurs when there is too much fluid in the lungs. This fluid gathers in the lungs' many air sacs, making breathing harder. Cardiac issues usually cause pulmonary edema. Pulmonary edema can be acute, appears suddenly, or chronic. It develops over time. If the patient is treated quickly, the prognosis improves. Supplemental oxygen and medicines are commonly used to treat pulmonary edema, depending on the reason.
Pulmonary Edema Therapeutics Market Dynamics
Increasing biomarkers to diagnose Pulmonary Edema is expected to drive market growth.
Biomarkers to diagnose pulmonary edema are becoming more common in recent diagnostic evaluations. A biomarker is a detectable sign of a particular biological state or situation, like a disease process. Clinical examination and imaging testing are the most prevalent procedures for diagnosing pulmonary edema. Blood tests are also useful for detecting disease by looking for biomarkers in the blood. Biomarkers are less expensive than other types of evaluation tests.
Also, these devices can identify other cardiac or kidney disorders. Moreover, the high prevalence of cardiovascular diseases such as carotid artery disease, cardiomyopathy, heart valve problems, and hypertension has increased the demand for therapeutics. Thus, the market is expected to drive in the forecast period.
COVID-19 Impact Analysis
The COVID-19 pandemic has moderately impacted healthcare systems and the market. The primary cause of COVID-19 mortality is aberrant alveolar fluid metabolism in the lungs, which results in fluid buildup in the alveolar airspace. This illness is known as pulmonary edema and is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In severe Coronavirus Disease (COVID-19) individuals, numerous potential processes cause pulmonary edema, and identifying those pathways may help with the care of this condition. The aberrant lung humoral metabolism has received little consideration among the current COVID-19 treatment options. Surprisingly, good lung humoral metabolism balance may reduce COVID-19 deaths, limiting the potential of healthcare facilities lacking the capacity to deliver ventilator-assisted respiration. In contrast, the pandemic is interrupting the supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the COVID-19 pandemic has affected the market.
Pulmonary Edema Therapeutics Market Segment Analysis
Cardiogenic pulmonary edema segment is expected to hold the largest market share in pulmonary edema therapeutics market
The cardiogenic pulmonary edema segment is expected to dominate in 2020. The segment benefits because it is most common, and increased pressures in the heart cause it. It's usually a result of heart failure. When a diseased or overworked left ventricle can't pump out enough of the blood it gets from your lungs, pressures in the heart go up. The increased pressure pushes fluid through the blood vessel walls into the air sacs. The medical conditions that can cause heart failure and lead to pulmonary edema include Coronary artery disease, Cardiomyopathy, Heart valve problems, High blood pressure (hypertension), and other heart problems cause it. Therefore, it has increased the demand for the treatment, due to which the market segment is expected to hold the largest market share in the forecast period.
Pulmonary Edema Therapeutics Market Scope and Summary
| Metrics | Details |
| Market CAGR | 3.3% |
| Segments Covered | By Drug Class, By Type, By Route of Administration, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
Pulmonary Edema Therapeutics Market Geographical Analysis
North America region holds the largest market share in the global pulmonary edema therapeutics market
In 2020, North America accounted for the highest revenue share. The increasing prevalence of pulmonary edema, rising geriatric population, well-established infrastructure, rising health care investments and rising affordability of drugs, product launches and collaborations by the key market players in the region are some of the factors the market is expected to boost in the forecast period. For instance, Pulmonary edema commonly affects individuals older than 65 years of age. Males are more commonly affected by pulmonary edema than a woman. More than a million Americans are diagnosed with pulmonary edema each year, yet many people don't know the condition or whether they're at risk. Moreover, On May 8, 2020, Amgen Inc. and Cytokinetics Inc. announced that the US Food and Drug Administration (FDA) had granted omecamtiv mecarbil, a novel selective cardiac myosin activator, also known as cardiac myotrope, Fast Track designation for the potential treatment of chronic heart failure with reduced ejection fraction (HFrEF). Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Pulmonary Edema Therapeutics Market Competitive Landscape
Major key players in the pulmonary edema therapeutics market are Pfizer Inc., sanofi-aventis U.S. LLC, Purdue Phanna L.P., Evus Pharmaceuticals, LLC , NovaDel Pharma Inc., American Regent, Inc., Medicure Inc. and Copperhead Chemical Company.
Pfizer Inc.:
Overview:
Pfizer Inc. is an American multinational pharmaceutical company. The company develops and produces medicines and vaccines for various medical disciplines, including immunology, oncology, cardiology, endocrinology, neurology and other therapeutic areas. Its medicines and vaccines provide value for healthcare providers and patients through the treatment of diseases improvements in health wellness. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.
Product Portfolio:
FUROSEMIDE (furosemide): Furosemide belongs to a group of medicines called loop diuretics (also known as water pills). It is given to help treat fluid retention (edema) and swelling caused by congestive heart failure, liver disease, kidney disease, or other medical conditions.
